Business & Finance
Business and Finance
Business and Finance
Mon, July 19, 2010 Rodman & Renshaw Announces Analyst Discussion with Cleveland BioLabs, Inc.
NEW YORK--([ BUSINESS WIRE ])--Rodman& Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), a leading full service investment bank for growth companies today announced that on August 10, 2010, Rodman will host an analyst discussion in its media center with Michael Fonstein, Ph.D., President and Chief Executive Officer, and Andrei Gudkov, Ph.D., D. Sci., Chief Scientific Officer, of Cleveland BioLabs, Inc.
The event will be hosted by Simos Simeonidis, Ph.D., Senior Biotechnology Analyst, of Rodman & Renshaw, LLC. The topics to be covered will include a discussion of the companya™s pipeline compounds, and will include the latest update on CBLIa™s lead program, CBLB502, currently in development for the treatment of Acute Radiation Syndrome.
The analyst discussion will take place at Rodman & Renshawa™s offices (1251 Avenue of the Americas, 20th Floor, New York, NY 10020)at 4:30PM ET on August 10th, 2010. To attend, please RSVP to Marta Wypych at [ mwypych@rodm.com ]. This event will also be webcasted live at Rodman TV ([ www.rodm.tv ]). Advance registration is required at least 30 minutes prior to the start of the broadcast. The event can also be accessed via conference line. Investors should contact your sales representative at Rodman & Renshaw for the dial-in information or visit Rodman TV for the archived video - which will be available 24 hours after the completion of the event.
Background of Management:
Michael Fonstein, Ph.D.
Dr. Fonstein has served as Cleveland BioLabsa™s Chief Executive Officer and President and as a director since the companya™s inception in June 2003. Prior to this he served as Director of the DNA Sequencing Center at the University of Chicago from its creation in 1994 to 1998, when he left to found Integrated Genomics, Inc. located in Chicago, Illinois. He served as CEO and President of Integrated Genomics from 1997 to 2003. Dr. Fonstein has won several business awards, including the Incubator of the Year Award from the Association of University Related Research Parks. He was also the winner of a coveted KPMG Illinois High Tech Award.
Andrei Gudkov, Ph.D.
Dr. Gudkov has served as Cleveland BioLabsa™s Chief Scientific Officer and as a director since the companya™s inception in June 2003. Prior to 1990, he worked at The National Cancer Research Center in Moscow (USSR) where he led a broad research program focused on virology and cancer drug resistance. In 1990, he reestablished his lab at the University of Illinois at Chicago where he became a tenured faculty member in the Department of Molecular Genetics. His lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic where he became Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. In 2007, Dr. Gudkov accepted the position of Senior VP Basic Science and Chair, Department of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, NY. Dr. Gudkov is not employed full time by the company, but rather divides time between work for CBLI and for Roswell Park.
About Cleveland BioLabs, inc.
Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a pipeline of drugs for multiple medical and defense applications. CBLIa™s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute.
AboutRodman & Renshaw Capital Group, Inc.
Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.
Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005.
For more information visit Rodman & Renshaw on the Internet at [ www.rodm.com ].
MEMBER FINRA, SIPC
